Moderna rises on $2.25 billion settlement, clearing COVID vaccine patent dispute overhang

By Puyaan Singh March 4 (Reuters) - Moderna shares rose 9% on Wednesday after it settled a long-running legal battle over the ...

Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute

By Kamal Choudhury and Blake Brittain March 3 (Reuters) - Moderna has agreed to pay Genevant Sciences, a subsidiary of ...

Moderna shares rise on $2.25-billion settlement over COVID-19 vaccine technology

Moderna will pay US$950-million upfront in July, 2026, with an additional US$1.3-billion contingent on the outcome of a separate legal appeal, while not owing royalties for the technology in its ...

Moderna Vaccine Patent Deal Sets Up High-Stakes Immunity Appeal

Moderna Inc.’s settlement to end a lawsuit over technology used in its Covid-19 vaccine caps its potential exposure at $2.25 ...
MedCity News

Moderna to Pay Up to $2.25B to Settle Patent Suit Over Covid-19 Vaccine Technology

Under the settlement, Genevant Sciences and Arbutus Biopharma will grant Moderna a non-exclusive license to their lipid nanoparticle technology for mRNA delivery in infectious disease vaccines. If ...
HealthLeaders Media

Moderna rises as up to $2.25B settlement for COVID vaccine patent dispute to remove overhang

Moderna shares rose 10% in premarket trading on Wednesday after the company settled a long-running legal battle over the ‌technology that made its COVID-19 vaccine possible, removing an overhang and ...

After flu vaccine hiccups, potential $2.25 billion settlement, where does Moderna go from here?

Moderna has managed to eke out some temporary wins, paving the way for the homegrown biotech to focus on its next moves.

FDA refuses Moderna's application for new mRNA flu vaccine

The Food and Drug Administration is refusing to consider Moderna's application for a new flu vaccine made with mRNA technology, the company said.